What are the recent trends in market size and growth for the anti-parkinson drugs market?
The anti-parkinson drugs market size has grown strongly in recent years. It will grow from $10.37 billion in 2024 to $11.08 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to aging population, increasing disease prevalence, healthcare infrastructure, advancements in research.
The anti-parkinson drugs market size is expected to see strong growth in the next few years. It will grow to $13.73 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to growing awareness, biotechnological advancements, emerging markets. Major trends in the forecast period include investment in r&d, personalized medicine, disease-modifying therapies, drug repurposing, telemedicine and remote monitoring, biosimilars, research collaborations.
Get Your Free Sample of The Global Anti-Parkinson Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3462&type=smp
How have varous drivers impacted the growth of the anti-parkinson drugs market?
The increasing geriatric population and surging cases of Parkinson’s disease (PD) are projected to drive the demand for the anti-Parkinson drugs market. PD commonly occurs in people over the age of 60 cases of Parkinson’s disease (PD) are projected to drive the demand for the anti-Parkinson drugs market. PD commonly occurs in people over the age of 60. For instance, in October 2022, according to the World Health Organization, a US-based health agency, Globally, 1 in 6 individuals will be 60 or older by 2030, and by 2050, there will be a double amount of individuals in this age group (2.1 billion). Therefore, the increasing geriatric population is driving the growth of the anti-parkinson drugs market.
What are the primary segments of the anti-parkinson drugs market?
The anti-parkinson drugs market covered in this report is segmented –
1) By Drugs Class: Levodopa Or Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Other Drugs
2) By Route of Administration: Oral, Injection, Transdermal
3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies
Subsegments:
1) By Levodopa Or Carbidopa: Immediate-Release Levodopa Or Carbidopa, Extended-Release Levodopa Or Carbidopa
2) By Dopamine Receptor Agonists: Pramipexole, Ropinirole, Rotigotine
3) By Monoamine Oxidase Type B (MAO-B) Inhibitors: Selegiline, Rasagiline, Safinamide
4) By Catechol-O-Methyltransferase (COMT)-Inhibitors: Entacapone, Tolcapone
5) By Anticholinergics: Benztropine, Trihexyphenidyl
6) By Other Drugs: Amantadine, Apomorphine
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report
Which firms are leading the anti-parkinson drugs market?
Major companies operating in the anti-parkinson drugs market include GlaxoSmithKline plc, Pfizer Inc., Merck Co., Novartis AG, F. Hoffmann-La Roche AG, UCB S.A, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Mylan NV, C.H. Boehringer Sohn AG & Co. KG, Orion Pharma Ltd., ACADIA Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., US WorldMeds LLC, Zydus Lifesciences Limited, Chemical Industrial & Pharmaceutical Laboratories Ltd., Strides Shasun Ltd., Axcan Pharma Inc., Upsher-Smith Laboratories LLC, H. Lundbeck A/S, Vertical Pharmaceuticals LLC, Zambon SPA, M Somerset Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc.
How will industry trends affect the trajectory of the anti-parkinson drugs market?
Major companies operating in the anti-Parkinson drugs market are focused on developing advanced therapeutic solutions such as motor fluctuations and dyskinesia to enhance symptom control and minimize side effects. Motor fluctuations and dyskinesia often complicate the treatment of Parkinson’s disease, affecting patient well-being. For instance, in January 2024, AbbVie Inc., a US-based pharmaceutical company, launched PRODUODOPA. PRODUODOPA(foslevodopa/foscarbidopa) is the first subcutaneous 24-hour infusion therapy for advanced Parkinson’s disease, specifically addressing severe motor fluctuations and dyskinesia when other treatments fail. It continuously delivers levodopa, potentially increasing ‘on’ time and improving symptom control.
Which geographic trends are shaping the anti-parkinson drugs market, and which region has the highest market share?
North America was the largest region in the anti-Parkinson drugs market in 2023. Middle East is expected to be the fastest-growing region in the anti-parkinson drugs market during the forecast period. The regions covered in the anti-parkinson drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Does The Anti-Parkinson Drugs Market Report 2025 Offer?
The anti-parkinson drugs market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Anti-Parkinson drug is a term used to describe the medications that are mostly used to treat Parkinson’s disease. They are not psychiatric medications, so they cannot legally be used to treat mental health issues. However, a doctor or psychiatrist may recommend one of these medications in addition to an antipsychotic to lessen some of the antipsychotic’s negative effects.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3462
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
